Vı́tězslav Kolek - Concepedia

Author

Vı́tězslav Kolek

Also Known As

IPF registry, Kolek Vitezslav, VITEZSLAV KOLEK, Vitezslav Kolek, Vitězslav Kolek, VÍTĚZSLAV KOLEK, VíTězslav Kolek, Vítezslav Kolek, Vítĕzslav Kolek, Vítězslav KOLEK

260

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Palacký University Olomouc University Hospital Olomouc Institute of Molecular and Translational Medicine Charles University Royal Brompton Hospital

About

Vı́tězslav Kolek is an author at Palacký University Olomouc specializing in medicine, pathology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	3.6K
2	Public Health	5	5	354
3	Allergy	3	3	68
4	Cell Biology	1	1	19
5	Emergency Medicine	1	1	18

Vı́tězslav Kolek

Publications

8.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, The Lancet Oncology Platinum–etoposide Versus Platinum–etoposideMedicinePathologyImmune Checkpoint InhibitorFirst-line Treatment	2020	662
Phenotypes of organ involvement in sarcoidosis Jonas C. Schupp, Sandra Freitag‐Wolf, Elena Bargagli, European Respiratory Journal ImmunologyGenetic EpidemiologyPathologyDermatologyOrgan Involvement	2018	237
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial Petr Zatloukal, Luboš Petruželka, Milada Zemanová, Lung Cancer MedicinePhase IiiMetronomic TherapyPathologyBronchial Neoplasm	2003	161
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Journal of Thoracic Oncology	2019	141
Interleukin-1 Gene Cluster Polymorphisms in Sarcoidosis and Idiopathic Pulmonary Fibrosis Beata Hutyrová, Panagiotis Pantelidis, Monika Žůrková, American Journal of Respiratory and Critical Care Medicine	2002	134
CC Chemokine Receptor Gene Polymorphisms in Czech Patients with Pulmonary Sarcoidosis Martin Petřek, Vı́tězslav Kolek, Jaroslav Zlámal, American Journal of Respiratory and Critical Care Medicine	2000	113
Human Leukocyte Antigen-DRB1 Position 11 Residues Are a Common Protective Marker for Sarcoidosis Patrick J. Foley, Deirdre S. McGrath, Elżbieta Puścińska, American Journal of Respiratory Cell and Molecular Biology	2001	107
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka, The Lancet Respiratory Medicine FibrosisExtracellular Matrix TurnoverInflammatory Lung DiseaseLung InflammationIdiopathic Pulmonary Fibrosis	2019	96

Page 1